January 2024

– Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy – – Preliminary survival analysis of ADG12

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: